↓ Skip to main content

Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)

Overview of attention for article published in Annals of the Rheumatic Diseases, July 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (96th percentile)
  • High Attention Score compared to outputs of the same age and source (94th percentile)

Citations

dimensions_citation
435 Dimensions

Readers on

mendeley
231 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)
Published in
Annals of the Rheumatic Diseases, July 2012
DOI 10.1136/annrheumdis-2012-201766
Pubmed ID
Authors

Joachim Sieper, Désirée van der Heijde, Maxime Dougados, Philip J Mease, Walter P Maksymowych, Matthew A Brown, Vipin Arora, Aileen L Pangan

Abstract

To evaluate the efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis (nr-axSpA).

X Demographics

X Demographics

The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 231 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Germany 1 <1%
Netherlands 1 <1%
Brazil 1 <1%
United Kingdom 1 <1%
Canada 1 <1%
Singapore 1 <1%
Unknown 225 97%

Demographic breakdown

Readers by professional status Count As %
Other 34 15%
Student > Ph. D. Student 34 15%
Researcher 32 14%
Student > Master 20 9%
Student > Postgraduate 16 7%
Other 45 19%
Unknown 50 22%
Readers by discipline Count As %
Medicine and Dentistry 119 52%
Pharmacology, Toxicology and Pharmaceutical Science 14 6%
Agricultural and Biological Sciences 9 4%
Immunology and Microbiology 5 2%
Nursing and Health Professions 5 2%
Other 21 9%
Unknown 58 25%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 31. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 July 2021.
All research outputs
#1,257,707
of 25,045,181 outputs
Outputs from Annals of the Rheumatic Diseases
#694
of 7,753 outputs
Outputs of similar age
#6,754
of 169,950 outputs
Outputs of similar age from Annals of the Rheumatic Diseases
#6
of 98 outputs
Altmetric has tracked 25,045,181 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 7,753 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.1. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 169,950 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 98 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.